ReviewNeuropsychopharmacology reports2021
Discovery research and development history of the dopamine D
Review in Neuropsychopharmacology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Is Aripiprazole an Effective Adjunct to Reduce Metabolic Adverse Effects Caused by Clozapine in Patients With Schizophrenia-A Systematic Review.Neuropsychopharmacology reports · 2026Pooled it
- Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports.Psychopharmacology · 2024Pooled it
- Trial
- Brexpiprazole vs. Aripiprazole in Patients with Schizophrenia with or Without Comorbid Substance Use Disorder: A 12-Month Real-World Naturalistic Study of Efficacy.Brain sciences · 2026Article
- Efficacy and safety of 2-4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta-analysis.PCN reports : psychiatry and clinical neurosciences · 2026Review
- Article
- Real-world use of brexpiprazole during inpatient treatment for schizophrenia: continuation, discontinuation, and concomitant psychotropics.Frontiers in psychiatry · 2026Article
- Rescue of cognitive and negative-like symptoms by chronic aripiprazole treatment in a 3-hit mouse model of neurodevelopmental disorder.Frontiers in pharmacology · 2026Article
- Review
- Long-Acting Injectable Antipsychotic Use and Discontinuation Rates in Children and Adolescents With Schizophrenia Using Medicaid Claims Data.Early intervention in psychiatry · 2025Article
- Survey on the Initiation of Aripiprazole Once-Monthly via a Two-Injection Start in Adult Patients with Schizophrenia: Experience of European Healthcare Professionals.Advances in therapy · 2025Article
- Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment.Neuropsychiatric disease and treatment · 2025Article
- Sexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis.PloS one · 2025Article
- Advancements in Managing Schizophrenia through Classical Approaches, Mechanisms, and Deep Brain Stimulation.Current pharmaceutical design · 2025Review
- Article
- Effects ofBiochemistry and biophysics reports · 2024Article
- G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.Signal transduction and targeted therapy · 2023Review
- Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study.Neuropsychopharmacology reports · 2023Article
- Brexpiprazole-Pharmacologic Properties and Use in Schizophrenia and Mood Disorders.Brain sciences · 2023Review
- Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms.Pharmacological reports : PR · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.